Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): The Experience at European Institute of Oncology (EIO)

Anna Vanazzi, MD, Safaa Ramadan, PhD MD, Francesca De Lorenzi, MD, Paola Arena, MD, Enrico Derenzini, MD PhD, Mario Rietjens, Anna Rotili, MD, Antuono Latronico, MD, Laura Travaini, MD, Emanuela Omodeo Sale', Daniela Malengo, Marianna Gerardi, Stefano Fiori, MD, Valentina Tabanelli, MD, Stefano A Pileri, Corrado Tarella, MD

Blood (2019) 134 (Supplement_1): 5283.

https://doi.org/10.1182/blood-2019-125239

Published: 2019

Journal Articles

Lymphoma Occurring during Pregnancy: Obstetric Outcome and Overall Survival in a Series of 19 Patients

Anna Vanazzi, MD, Fedro Peccatori, MD, Barbara Buonomo, MD, Di Loreto Eugenia, MD, Giovanna Scarfone, MD, Stefano A Pileri, Corrado Tarella, MD

Blood (2019) 134 (Supplement_1): 5289.

https://doi.org/10.1182/blood-2019-127391

Published: 2019

Journal Articles

Integration of Nanostring Profiling and Functional Characterization of Oxidative and Replicative Stress Biomarkers Identifies Poor Prognosis MYC/BCL-2 Positive Diffuse Large B-Cell Lymphoma Subsets, Providing Opportunities for Precision Therapies

Enrico Derenzini, MD PhD, Alessandra Rossi, PhD, Claudio Agostinelli, MD, Maura Rossi, PhD, Federica Melle, PhD, Giovanna Motta, PhD, Marco Fabbri, PhD, Tommaso Radice, MD, Safaa Ramadan, PhD MD, Anna Vanazzi, MD, Valentina Tabanelli, MD, Stefano Fiori, MD, Annalisa Chiappella, MD, Alberto Agazzi, MD, Pier Luigi Zinzani, MD, Umberto Vitolo, Corrado Tarella, MD Prof, Stefano A. Pileri, MD PhD

Blood (2018) 132 (Supplement 1): 676.

https://doi.org/10.1182/blood-2018-99-118329

Published: 2018

Journal Articles

Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03

Christian Taverna, MD, Giovanni Martinelli, MD, Felicitas Hitz, MD, Walter Mingrone, MD, Thomas Pabst, MD PhD, Lidija Cevreska, MD PhD, Auro del Giglio, MD, Anna Vanazzi, MD, Daniele Laszlo, MD, Johann Raats, Daniel Rauch, Daniel Vorobiof, Andreas Lohri, MD, Emanuele Zucca, Celine Rueegsegger, Stephanie - Rondeau, Corinne Rusterholz, Michele Ghielmini

Blood (2018) 132 (Supplement 1): 1601.

https://doi.org/10.1182/blood-2018-99-116864

Published: 2018

Journal Articles

Real-World Data of Nivolumab in Classical Hodgkin Lymphoma: Results from the Italian Expanded Access Programme

Blood (2017) 130 (Supplement 1): 5171.

https://doi.org/10.1182/blood.V130.Suppl_1.5171.5171

Published: 2017

Journal Articles

Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

Blood (2016) 128 (22): 1099.

https://doi.org/10.1182/blood.V128.22.1099.1099

Published: 2016

Journal Articles

Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Anaplastic Large Cell Lymphoma

Blood (2016) 128 (22): 3007.

https://doi.org/10.1182/blood.V128.22.3007.3007

Published: 2016

Journal Articles

Prognostic Value of End of Treatment FDG-PET Scan in T-Cell Lymphoma, a 20-Year Single Institution Study

Enrico Derenzini, MD PhD, Angela Gueli, MD, Safaa Ramadan, PhD MD, Anna Vanazzi, MD, Simona Sammassimo, MD, Federica Gigli, MD, Niccolo' Frungillo, MD, Riccardo Bruna, MD, Alberto Agazzi, MD, Alberto De Crescenzo, MD, Rocco Pastano, MD, Laura L Travaini, MD, Chiara Grana, MD, Laszlo Daniele, MD, William Arcese, Corrado Tarella, MD

Blood (2016) 128 (22): 3003.

https://doi.org/10.1182/blood.V128.22.3003.3003

Published: 2016

Journal Articles

90 y-Ibritumomab Tiuxetan or Purine Analogues Severely Affect Peripheral Blood Stem Cell Mobilization: An Analysis On 248 Patients.

Anna Vanazzi, MD, Alessandra Alietti, MD, Alberto Agazzi, MD, Mara Negri, Maria Teresa Lionetti, Aleksandra Babic, Davide Radice, Luca Nassi, MD, Simona Sammassimo, MD, Cristina Rabascio, Pierluigi Antoniotti, Lara Roveda, Bruno Lucchetti, Tiziana Suardi, Alessio Piredda, Liliana Calabrese, Giovanni Martinelli, MD, Daniele Laszlo, MD

Blood (2009) 114 (22): 3210.

https://doi.org/10.1182/blood.V114.22.3210.3210

Published: 2009

Journal Articles

Rituximab and Chlorambucil as Front-Line Treatment in Untreated Follicular Lymphoma: a Combination with a Durable Response and Low Toxicity Profile.

Simona Bassi, MD, Luca Nassi, MD, Giancarlo Pruneri, MD, Simona Sammassimo, MD, Paola Bertazzoni, MD, Federica Gigli, MD, Anna Vanazzi, MD, Emilia Cocorocchio, MD, Patrizia Mancuso, Cristina Rabascio, Maria Teresa Lionetti, Daniele Laszlo, MD, Giovanni Martinelli, MD

Blood (2009) 114 (22): 3754.

https://doi.org/10.1182/blood.V114.22.3754.3754

Published: 2009

Journal Articles

Evolving First-Line Treatments -from Chemotherapy to Immunotherapy Alone- in 143 Consecutive Follicular Lymphoma Patients Treated in the Last 14 Years at the European Institute of Oncology, Milano

Simona Bassi, MD, Federica Gigli, Cristina Rabascio, Simona Sammassimo, Patrizia Mancuso, Emilia Cocorocchio, Paola Bertazzoni, Daniele Laszlo, Giancarlo Pruneri, Liliana Calabrese, Maria Teresa Lionetti, Anna Vanazzi, MD, Alessandra Alietti, Luca Nassi, Alberto Agazzi, Rocco Pastano, Fedro Alessandro Peccatori, Giovanni Martinelli

Blood (2008) 112 (11): 5016.

https://doi.org/10.1182/blood.V112.11.5016.5016

Published: 2008

Journal Articles

High Dose 90Yttrium Ibritumomab Tiuxetan with PBSC Support in Refractory-Resistant NHL Patients.

Anna Vanazzi, MD, Pier Francesco Ferrucci, MD, Chiara Grana, MD, Marta Cremonesi, MPh, Margherita Clerici, RN, Davide Radice, ST, Stefano Papi, PhD, Liliana Calabrese, DM, Giovanni Paganelli, MD, Giovanni Martinelli, MD

Blood (2007) 110 (11): 1890.

https://doi.org/10.1182/blood.V110.11.1890.1890

Published: 2007

Journal Articles

Efficacy of 90Y-Ibritumomab Tiuxetan in Marginal-Zone Lymphoma (MZL).

Anna Vanazzi, MD, Pier Francesco Ferrucci, MD, Chiara Grana, MD, Giancarlo Pruneri, MD, Cristiano Crosta, MD, Antonello Pinto, MD, Marco Chinol, PhD, Giovanni Paganelli, MD, Giovanni Martinelli, MD

Blood (2007) 110 (11): 4499.

https://doi.org/10.1182/blood.V110.11.4499.4499

Published: 2007

Journal Articles

High Dose 90 Yttrium Ibritumomab Tiuxetan (Zevalin) with PBSC Support in Refractory-Resistant NHL Patients: A Phase I/II Study.

Anna Vanazzi, MD, Pier Francesco Ferrucci, MD, Chiara Grana, MD, Marta Cremonesi, MPH, Margherita Clerici, RN, Davide Radice, ST, STefano Papi, Liliana Calabrese, DM, Giovanni Paganelli, MD, Giovanni Martinelli, MD

Blood (2006) 108 (11): 2720.

https://doi.org/10.1182/blood.V108.11.2720.2720

Published: 2006

Journal Articles

Efficacy of 90 Y-Ibritumomab Tiuxetan (Zevalin) in Refractory or Relapsed MALT Gastric Non Hodgkin’s Lymphoma.

Anna Vanazzi, MD, Pier F. Ferrucci, MD, Chiara Grana, MD, Giancarlo Pruneri, MD, Cristiano Crosta, MD, Antonello Pinto, MD, Marco Chinol, Giovanni Paganelli, MD, Giovanni Martinelli, MD

Blood (2006) 108 (11): 2771.

https://doi.org/10.1182/blood.V108.11.2771.2771

Published: 2006

Journal Articles

Tissue Microarray (TMA) Study in DLBC Lymphomas (DLBCL): Could the Extranodal Origin Affect the Prognostic Impact of the Analysis?.

Daniele Laszlo, MD, Giancarlo Pruneri, MD, Giovanna Andreola, MD, Davide Radice, ST, Liliana Calabrese, DM, Alessandra Alietti, MD, Alberto Agazzi, MD, Anna Vanazzi, MD, Giovanni Martinelli, MD

Blood (2006) 108 (11): 2037.

https://doi.org/10.1182/blood.V108.11.2037.2037

Published: 2006

Journal Articles

High Dose Zevalin (90Yttrium Ibritumomab Tiuxetan) Treatment with PBSC Support in Refractory-Resistant NHL Patients: Preliminary Results of a Phase I/II Study.

Anna Vanazzi, MD, Pierfrancesco Ferrucci, MD, Mahila Ferrari, Liliana Calabrese, Marta Cremonesi, Mirco Bartolomei, MD, Giovanni Paganelli, MD, Giovanni Martinelli, MD

Blood (2005) 106 (11): 488.

https://doi.org/10.1182/blood.V106.11.488.488

Published: 2005

NARROW

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): The Experience at European Institute of Oncology (EIO)

Lymphoma Occurring during Pregnancy: Obstetric Outcome and Overall Survival in a Series of 19 Patients

Integration of Nanostring Profiling and Functional Characterization of Oxidative and Replicative Stress Biomarkers Identifies Poor Prognosis MYC/BCL-2 Positive Diffuse Large B-Cell Lymphoma Subsets, Providing Opportunities for Precision Therapies

Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03

Real-World Data of Nivolumab in Classical Hodgkin Lymphoma: Results from the Italian Expanded Access Programme

Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Anaplastic Large Cell Lymphoma

Prognostic Value of End of Treatment FDG-PET Scan in T-Cell Lymphoma, a 20-Year Single Institution Study

90 y-Ibritumomab Tiuxetan or Purine Analogues Severely Affect Peripheral Blood Stem Cell Mobilization: An Analysis On 248 Patients.

Rituximab and Chlorambucil as Front-Line Treatment in Untreated Follicular Lymphoma: a Combination with a Durable Response and Low Toxicity Profile.

Evolving First-Line Treatments -from Chemotherapy to Immunotherapy Alone- in 143 Consecutive Follicular Lymphoma Patients Treated in the Last 14 Years at the European Institute of Oncology, Milano

High Dose 90Yttrium Ibritumomab Tiuxetan with PBSC Support in Refractory-Resistant NHL Patients.

Efficacy of 90Y-Ibritumomab Tiuxetan in Marginal-Zone Lymphoma (MZL).

High Dose 90 Yttrium Ibritumomab Tiuxetan (Zevalin) with PBSC Support in Refractory-Resistant NHL Patients: A Phase I/II Study.

Efficacy of 90 Y-Ibritumomab Tiuxetan (Zevalin) in Refractory or Relapsed MALT Gastric Non Hodgkin’s Lymphoma.

Tissue Microarray (TMA) Study in DLBC Lymphomas (DLBCL): Could the Extranodal Origin Affect the Prognostic Impact of the Analysis?.

High Dose Zevalin (90Yttrium Ibritumomab Tiuxetan) Treatment with PBSC Support in Refractory-Resistant NHL Patients: Preliminary Results of a Phase I/II Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only